Related Experiment Video
Updated: Jul 16, 2026
Orthotopic Xenografting of Human Luciferase-Tagged Malignant Peripheral Nerve Sheath Tumor Cells for in vivo Testing of Candidate Therapeutic Agents
Published on: March 7, 2011
SSX antigens as tumor vaccine targets in human sarcoma
Maha Ayyoub1, Michelle Brehm, Geneviève Metthez
1Ludwig Institute Clinical Trial Center, Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.
Abstract:
The efficacy of current standard therapies for the treatment of sarcoma remains limited. With the aim of identifying target antigens relevant to the development of vaccine-based immunotherapy of sarcoma, we have addressed the relevance of tumor-specific antigens encoded by genes belonging to the SSX family as vaccine targets in sarcoma tumors. Expression of SSX-1 to -5 was analyzed in a collection of sarcoma tumors of diverse histological subtypes and in sarcoma cell lines. We found expression of at least one SSX-encoded antigen in 42% of sarcoma tumors, including 5 of 7 different histological subtypes, and in 50% of sarcoma cell lines. SSX-1 was the most frequently expressed family member, followed by SSX-4, -2 and -5. Expression of SSX-3 was detected in only one sample. Importantly, most SSX positive samples co-expressed more than one family member. In addition, assessment of CD8+ T cell recognition of HLA-A2+ SSX-2+ sarcoma cells showed that the latter were efficiently recognized and lysed by SSX-2-specific CTLs. The results of this study indicate that SSX antigens are relevant targets for the development of vaccine-based immunotherapy of sarcoma and encourage the start of vaccination trials using SSX-derived immunogens in sarcoma patients.
Insights
SSX antigens are promising targets for sarcoma immunotherapy. These tumor-specific antigens are expressed in 42% of sarcomas, showing potential for vaccine development against this cancer.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Current sarcoma therapies have limited efficacy.
- There is a need for novel therapeutic strategies, such as immunotherapy.
- Tumor-specific antigens are key targets for effective cancer vaccines.
Purpose of the Study:
- To investigate the expression of SSX family antigens in sarcoma tumors.
- To evaluate SSX antigens as potential targets for sarcoma vaccine-based immunotherapy.
- To assess the immunogenicity of SSX antigens in sarcoma.
Main Methods:
- Analysis of SSX-1 to -5 gene expression in diverse sarcoma tumors and cell lines.
- Detection of SSX antigen expression using molecular techniques.
- Assessment of CD8+ T cell recognition and lysis of SSX-expressing sarcoma cells.
Main Results:
- At least one SSX antigen was expressed in 42% of sarcoma tumors and 50% of sarcoma cell lines.
- SSX-1 was the most frequent member expressed, followed by SSX-4, -2, and -5.
- SSX-2-specific cytotoxic T lymphocytes (CTLs) efficiently recognized and lysed SSX-2-positive sarcoma cells.
Conclusions:
- SSX antigens are frequently expressed across various sarcoma subtypes.
- SSX antigens represent viable targets for developing effective sarcoma immunotherapy vaccines.
- These findings support initiating vaccination trials with SSX-derived immunogens in sarcoma patients.
Related Concept Videos
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...